Tango Therapeutics, Inc. TNGX
Set alert
At close · Nov 2
After hours · Nov 2, 4:02 PM ET
- YTD
- +145.60%
- 1 year
- +168.31%
- Open
- 22.65
- Prev close
- 22.72
- Mkt cap
- 3.67B
- Vol
- 3.68M
- Avg vol
- 3.27M
- EPS
- -0.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.72
- High
- 23.31
- Forward P/E
- -12.91
- Beta
- 1.22
- Short ratio
- 11.90
- Inst. own
- 128.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 23.60
- 200-d avg
- 22.33
- 1y target
- 47.09
News
3 days ago seekingalpha.com
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
Tango Therapeutics upgraded from 'Hold' to 'Buy' following strong phase 1/2 data for vopimetostat + RASONQUE in MTAP-del, 2nd-line/3rd-line RAS-mutant PDAC. Company's combination therapy showed an…
-
4 days ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.
5 days ago seekingalpha.com
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. I view the ESMO-driven sell-off as overdone, given TNGX's…
1 week ago zacks.com
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
1 week ago seekingalpha.com
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
1 week ago benzinga.com
Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings
U.S. stocks fell Friday: Dow -1.12%, S&P 500 -0.43%, Nasdaq -0.13%. Energy and oil rose; SLB gained 7% on strong results.
1 week ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 week ago marketbeat.com
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for…
1 week ago benzinga.com
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers.
1 week ago benzinga.com
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
-
1 week ago benzinga.com
Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today…
1 week ago investors.com
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
1 week ago globenewswire.com
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib
1 week ago benzinga.com
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed as the Dow gained 400 points. Winnebago jumped 7% on an EPS beat, while Super Micro and SpaceX rallied on strong outlooks.
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.
-
2 weeks ago benzinga.com
Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the…
2 weeks ago globenewswire.com
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET
4 weeks ago defenseworld.net
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis
Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
1 month ago defenseworld.net
Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey
Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Tango Therapeutics (NASDAQ: TNGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
1 month ago defenseworld.net
Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX
Tidal Investments LLC acquired a new stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional…
1 month ago zacks.com
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
1 month ago benzinga.com
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
2 months ago globenewswire.com
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of…
2 months ago globenewswire.com
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to…
2 months ago defenseworld.net
Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX
Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the…
2 months ago defenseworld.net
Tango Therapeutics, Inc. $TNGX Shares Sold by Bank of America Corp DE
Bank of America Corp DE trimmed its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 31.6% in the first quarter, according to the company in its most recent disclosure with the Securities and…
2 months ago defenseworld.net
ADAR1 Capital Management LLC Invests $2.40 Million in Tango Therapeutics, Inc. $TNGX
ADAR1 Capital Management LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $66 to $68.
2 months ago seekingalpha.com
Tango Therapeutics: Promising Early Data, But A Long Road Ahead
Vopimetostat's combination with daraxonrasib has produced an unusually strong early pancreatic-cancer signal, but the evidence still comes from a very small, previously treated cohort. A planned…
2 months ago zacks.com
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $32 to $35.
-
2 months ago benzinga.com
Tango Therapeutics Files Prospectus For Up To $400M Common Stock Offering
Up to $400,000,000Common StockWe have previously entered into a Sales Agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, dated November 21, 2025, relating to the sale…
-
2 months ago benzinga.com
Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate
Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 5.71 percent decrease over losses of…
-
3 months ago benzinga.com
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40
Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $36 to $40.
3 months ago benzinga.com
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.
-
3 months ago benzinga.com
JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46
JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $46.
-
4 months ago benzinga.com
Canaccord Genuity Maintains Buy on Tango Therapeutics, Raises Price Target to $46
Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $42 to $46.
-
4 months ago benzinga.com
Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60
Jefferies analyst Maury Raycroft upgrades Tango Therapeutics (NASDAQ:TNGX) from Hold to Buy and raises the price target from $27 to $60.
-
4 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $66
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $27 to $66.
4 months ago benzinga.com
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today
AAPL, SUNE, TNGX, APLD, CBRS were among the stocks seen trending on Monday, June 8, 2026.
-
4 months ago benzinga.com
Tango Therapeutics Launches $500M Common Stock Offering
Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the…
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
4 months ago benzinga.com
Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings
US stocks rose with Nasdaq up 400 points. Dow up 0.32%, Nasdaq up 1.55%, S&P 500 up 0.94%. Tech shares rose, communication services fell. Motorcar Parts of America stock jumped 37% on strong…
4 months ago benzinga.com
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and…
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 months ago benzinga.com
Why Is Tango Therapeutics Stock Soaring Monday?
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.
-
4 months ago benzinga.com
Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting…
5 months ago benzinga.com
Crude Oil Surges 3%; RBC Bearings Earnings Top Views
US stocks down, S&P 500 falls 1%; Dow down 1.08%, NASDAQ down 1.42%. Energy shares up 1.5%; materials stocks down 2.1%. RBC Bearings beats Q1 estimates.
-
5 months ago benzinga.com
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $30
Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $20 to $30.